Showing results (141-150 of 149) with videos related to
Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 149 results.
Cancer Research|May 8, 2007
An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanismsHelen Y Zou, Qiuhua Li, Joseph H Lee, et al.Journal of Medicinal Chemistry|August 29, 2012
Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancerJ Jean Cui, Michele McTigue, Mitchell Nambu, et al.Cancer Discovery|September 4, 2014
L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancerEun-Hee Shim, Carolina B Livi, Dinesh Rakheja, et al.Journal of Medicinal Chemistry|August 5, 2011
Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)J Jean Cui, Michelle Tran-Dubé, Hong Shen, et al.Circulation|June 14, 2024
Endothelial Heterogeneity in the Response to Autophagy Drives Small Vessel Muscularization in Pulmonary HypertensionQi Zhang, Nobuhiro Yaoita, Arata Tabuchi, et al.Proceedings of the National Academy of Sciences of the United States of America|March 4, 2015
PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutationsHelen Y Zou, Qiuhua Li, Lars D Engstrom, et al.Plos Genetics|April 4, 2015
Genome sequencing of the perciform fish Larimichthys crocea provides insights into molecular and genetic mechanisms of stress adaptationJingqun Ao, Yinnan Mu, Li-Xin Xiang, et al.Cancer Cell|July 7, 2015
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical ModelsHelen Y Zou, Luc Friboulet, David P Kodack, et al.Journal of Medicinal Chemistry|January 18, 2014
Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinibQinhua Huang, Ted W Johnson, Simon Bailey, et al.Pageof 15